On the basis of the findings above, we suggested that targeting SOS1 results in upregulating the expression of SLC22A4, thereby increasing the transport of imatinib, which ultimately leads to an increase in the imatinib sensitivity of CML cells. This evidence concerns the gene SOS1 and chronic myelogenous leukemia, BCR-ABL1 positive.